1. Home
  2. GHRS vs DAVA Comparison

GHRS vs DAVA Comparison

Compare GHRS & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • DAVA
  • Stock Information
  • Founded
  • GHRS 2018
  • DAVA 2000
  • Country
  • GHRS Ireland
  • DAVA United Kingdom
  • Employees
  • GHRS N/A
  • DAVA N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • DAVA EDP Services
  • Sector
  • GHRS Health Care
  • DAVA Technology
  • Exchange
  • GHRS Nasdaq
  • DAVA Nasdaq
  • Market Cap
  • GHRS 737.5M
  • DAVA 827.6M
  • IPO Year
  • GHRS 2021
  • DAVA 2018
  • Fundamental
  • Price
  • GHRS $14.76
  • DAVA $15.50
  • Analyst Decision
  • GHRS Strong Buy
  • DAVA Buy
  • Analyst Count
  • GHRS 8
  • DAVA 8
  • Target Price
  • GHRS $30.63
  • DAVA $26.75
  • AVG Volume (30 Days)
  • GHRS 204.8K
  • DAVA 810.1K
  • Earning Date
  • GHRS 05-08-2025
  • DAVA 05-14-2025
  • Dividend Yield
  • GHRS N/A
  • DAVA N/A
  • EPS Growth
  • GHRS N/A
  • DAVA N/A
  • EPS
  • GHRS N/A
  • DAVA 0.40
  • Revenue
  • GHRS N/A
  • DAVA $1,007,631,882.00
  • Revenue This Year
  • GHRS N/A
  • DAVA $6.33
  • Revenue Next Year
  • GHRS N/A
  • DAVA N/A
  • P/E Ratio
  • GHRS N/A
  • DAVA $38.97
  • Revenue Growth
  • GHRS N/A
  • DAVA 5.95
  • 52 Week Low
  • GHRS $6.00
  • DAVA $13.39
  • 52 Week High
  • GHRS $20.50
  • DAVA $34.94
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 66.16
  • DAVA 49.24
  • Support Level
  • GHRS $11.82
  • DAVA $13.39
  • Resistance Level
  • GHRS $12.94
  • DAVA $16.05
  • Average True Range (ATR)
  • GHRS 0.99
  • DAVA 0.61
  • MACD
  • GHRS 0.19
  • DAVA 0.16
  • Stochastic Oscillator
  • GHRS 84.53
  • DAVA 77.86

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

Share on Social Networks: